Company intelligence / Profile preview

rapid!

Lowell, Massachusetts, United States

Ownership: Private
Development stage: Commercial

Overview

Rapid Micro Biosystems has commercialized the Growth Direct® System—a fully automated platform for rapid and non-destructive detection of microbial contamination in pharmaceutical and biomanufacturing environments. The system accelerates quality control testing for environmental monitoring, water testing, bioburden and sterility testing. The company reported $28.1 million in revenue for full year 2024 (+25% YoY), with strong recurring revenue growth and expanding global partnerships.

Therapeutic areas: Other
Modalities: DeviceDiagnostic platform
Industry: Non-Drug Biotech

Partnerships

Merck KGaA (Life Science business)Charles River Laboratories InternationalSomaGenics CorporationWuXi AppTec

Beyond the preview

Go deeper on rapid!.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rapid!.

Explore the full profile